Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration
09/11/2023 13:17
Nov 9 (Reuters) - PharmAbcine Inc 208340.KQ :
* PHARMABCINE RECEIVES SAFETY REVIEW COMMITTEE APPROVAL TO
ADVANCE
TO DOSE LEVEL 2 OF CLINICAL TRIAL OF PMC-403 WITH NEOVASCULAR
AGE-RELATED MACULAR DEGENERATION FOLLOWING DOSE LEVEL 1 SAFETY
DATA
* PHARMABCINE INC - SAFETY REVIEW COMMITTEE EVALUATED DOSE
LEVEL 1
SAFETY DATA OF PMC-403 AND APPROVED ADVANCING TO HIGHER DOSE
TREATMENT.
Source text for Eikon: ID:nPn8yvHH9a
Further company coverage: 208340.KQ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on PharmAbcine
See all newsBrief: Pharmabcine Announces Safety Approval For 1st dose Cohort In Phase 1A/B Clinical Trial Of Pmc-309
Brief: Pharmabcine To Conduct Capital Increase Of 26 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 3.7 Billion Won For Operational Funds
Brief: Pharmabcine To Conduct Capital Increase Of 4.7 Billion Won For Operational Funds
Brief: PharmAbcine Receives Safety Review Committee Approval to Advance to Dose Level 2 of Clinical Trial of PMC-403 with Neovascular Age-related Macular Degeneration